Загрузка...
The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
BACKGROUND: Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed...
Сохранить в:
| Опубликовано в: : | Arthritis Res Ther |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5732524/ https://ncbi.nlm.nih.gov/pubmed/29246243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1482-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|